Skip to Content

Bamlanivimab Dosage

Applies to the following strengths: 700 mg/20 mL

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for COVID-19

For investigational use only

40 kg or greater:
700 mg IV over at least 60 minutes as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset

Comments:
-No data available regarding interchangeability of coronavirus disease 2019 (COVID-19) vaccine products.
-NOTE: The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of this unapproved product (bamlanivimab) for the treatment of mild to moderate coronavirus disease 2019 (COVID19).

Use: For the treatment of mild to moderate coronavirus disease 2019 (COVID19) in adults with positive results of direct SARS-CoV-2 viral testing who weigh at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization

Usual Pediatric Dose for COVID-19

For investigational use only

12 years and older:
40 kg or greater:
700 mg IV over at least 60 minutes via pump or gravity as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset

Comments:
-No data available regarding interchangeability of coronavirus disease 2019 (COVID-19) vaccine products.
-NOTE: The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of this unapproved product (bamlanivimab) for the treatment of mild to moderate coronavirus disease 2019 (COVID19).

Use: For the treatment of mild to moderate coronavirus disease 2019 (COVID19) in pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Dose Adjustments

No dose adjustment is recommended based on age, sex, race, body weight, renal or mild hepatic impairment, during pregnancy or while lactating, or for disease severity or inflammation.

Precautions

NOTE: The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of this unapproved product (bamlanivimab) for the treatment of mild to moderate coronavirus disease 2019 (COVID19) in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

CONTRAINDICATIONS:
-None

Safety and efficacy have not been established in patients younger than 12 years and/or less than 40 kg.

Dialysis

Data not available

Other Comments

NOTE: There is no adequate, approved and available alternative to this drug for patients who have mild to moderate COVID-19 who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Administration advice:
-This drug may only be administered in settings in which health care providers have immediate access to medications to treat a severe infusion reaction (e.g., anaphylaxis) and the ability to activate the emergency medical system (EMS).

Storage requirements:
-Refrigerate unopened vials at 2C to 8C (36F to 46F) in the original carton to protect from light; do not freeze, shake, or expose to direct light.

Reconstitution/preparation techniques:
-This drug is available as concentrated solution and must be diluted with 0.9% Sodium Chloride Injection prior to administration.
-Vials prior to dilution: The manufacturer product information should be consulted regarding storage and subsequent thawing of frozen vials.
-Vials after dilution: This product is preservative-free and should be administered immediately. If immediate administration is not possible, store the diluted solution for up to 24 hours at 2C to 8C (36F to 46F) or up to 7 hours at room temperature (20C to 25C [68F to 77F]) including infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes prior to administration.
-The manufacturer product information should be consulted.

General:
-This drug is not authorized for use in patients who are hospitalized due to COVID-19, OR who require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
-High risk patients are defined as those who meet at least one of the following criteria:
---Have a body mass index (BMI) of 35 or greater.
---Have chronic kidney disease.
---Have diabetes.
---Have immunosuppressive disease.
---Are currently receiving immunosuppressive treatment.
---Are 65 years or older.
---Are 55 years or older AND have cardiovascular disease OR hypertension OR chronic obstructive pulmonary disease/other chronic respiratory disease.
---Are 12 to 17 years of age AND have BMI greater than or equal to the 85th percentile for their age and gender based on CDC growth charts OR sickle cell disease OR congenital or acquired heart disease OR neurodevelopmental disorders (e.g., cerebral palsy) OR a medical-related technological dependence (e.g., tracheostomy, gastrostomy, positive pressure ventilation [not related to COVID-19] OR asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.

Monitoring:
-Monitor patients during infusion and for at least 1 hour after.

Patient advice:
-Patients treated with this drug should self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect "high touch" surfaces, and frequent handwashing) according to CDC guidelines.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.